IUPAC/Chemical Name
6-Chloro-2-(trichloromethyl)chromen-4-one
InChi Key
NTDHYMSVCBGQJF-UHFFFAOYSA-N
InChi Code
InChI=1S/C10H4Cl4O2/c11-5-1-2-8-6(3-5)7(15)4-9(16-8)10(12,13)14/h1-4H
SMILES Code
O=C1C=C(C(Cl)(Cl)Cl)OC2=C1C=C(Cl)C=C2
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO and DMF
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
ST034307 is an inhibitor of AC1 with an IC50 value of 2.3 µM for A23187-stimulated cAMP accumulation in HEK293 cells transfected with AC1.
In vivo activity:
AC1 inhibitors have potential as analgesic agents that treat pain and do not result in tolerance or cause disruption of normal behavior in mice. ST034307 relived pain in mouse models of formalin-induced inflammatory pain, acid-induced visceral pain, and acid-depressed nesting. ST034307 did not cause analgesic tolerance after chronic dosing.
Reference: Front Pharmacol. 2022 Jul 11;13:935588. https://pubmed.ncbi.nlm.nih.gov/35899113/
|
Solvent |
mg/mL |
mM |
comments |
| Solubility |
| DMF |
10.0 |
33.56 |
|
| DMSO |
5.0 |
16.78 |
|
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
297.94
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Bose SJ, Read MJ, Akerman E, Capel RA, Ayagama T, Russell A, Terrar DA, Zaccolo M, Burton RAB. Inhibition of adenylyl cyclase 1 by ST034307 inhibits IP3-evoked changes in sino-atrial node beat rate. Front Pharmacol. 2022 Aug 29;13:951897. doi: 10.3389/fphar.2022.951897. PMID: 36105228; PMCID: PMC9465815.
2. Giacoletti G, Price T, Hoelz LVB, Shremo Msdi A, Cossin S, Vazquez-Falto K, Amorim Fernandes TV, Santos de Pontes V, Wang H, Boechat N, Nornoo A, Brust TF. A Selective Adenylyl Cyclase 1 Inhibitor Relieves Pain Without Causing Tolerance. Front Pharmacol. 2022 Jul 11;13:935588. doi: 10.3389/fphar.2022.935588. PMID: 35899113; PMCID: PMC9310748.
In vivo protocol:
1. Bose SJ, Read MJ, Akerman E, Capel RA, Ayagama T, Russell A, Terrar DA, Zaccolo M, Burton RAB. Inhibition of adenylyl cyclase 1 by ST034307 inhibits IP3-evoked changes in sino-atrial node beat rate. Front Pharmacol. 2022 Aug 29;13:951897. doi: 10.3389/fphar.2022.951897. PMID: 36105228; PMCID: PMC9465815.
2. Giacoletti G, Price T, Hoelz LVB, Shremo Msdi A, Cossin S, Vazquez-Falto K, Amorim Fernandes TV, Santos de Pontes V, Wang H, Boechat N, Nornoo A, Brust TF. A Selective Adenylyl Cyclase 1 Inhibitor Relieves Pain Without Causing Tolerance. Front Pharmacol. 2022 Jul 11;13:935588. doi: 10.3389/fphar.2022.935588. PMID: 35899113; PMCID: PMC9310748.
1: Brust TF, Alongkronrusmee D, Soto-Velasquez M, Baldwin TA, Ye Z, Dai M, Dessauer CW, van Rijn RM, Watts VJ. Identification of a selective small-molecule inhibitor of type 1 adenylyl cyclase activity with analgesic properties. Sci Signal. 2017 Feb 21;10(467):eaah5381. doi: 10.1126/scisignal.aah5381. PMID: 28223412; PMCID: PMC5734633.
2: Cheng Y, Huang P, Meng B, Gan L, Wu D, Cao Y. Antinociceptive effects of the adenylyl cyclase inhibitor ST034307 on tooth-movement-induced nociception in rats. Arch Oral Biol. 2019 Feb;98:81-86. doi: 10.1016/j.archoralbio.2018.11.012. Epub 2018 Nov 14. PMID: 30465937.
3: Giacoletti G, Price T, Hoelz LVB, Shremo Msdi A, Cossin S, Vazquez-Falto K, Amorim Fernandes TV, Santos de Pontes V, Wang H, Boechat N, Nornoo A, Brust TF. A Selective Adenylyl Cyclase 1 Inhibitor Relieves Pain Without Causing Tolerance. Front Pharmacol. 2022 Jul 11;13:935588. doi: 10.3389/fphar.2022.935588. PMID: 35899113; PMCID: PMC9310748.
4: Bose SJ, Read MJ, Akerman E, Capel RA, Ayagama T, Russell A, Terrar DA, Zaccolo M, Burton RAB. Inhibition of adenylyl cyclase 1 by ST034307 inhibits IP3-evoked changes in sino-atrial node beat rate. Front Pharmacol. 2022 Aug 29;13:951897. doi: 10.3389/fphar.2022.951897. PMID: 36105228; PMCID: PMC9465815.
